A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs EC 1169 (Primary) ; EC 0652
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Endocyte
- 06 Feb 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Sep 2018.
- 23 Jul 2018 Planned End Date changed from 1 May 2018 to 1 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History